- Calcineurin Inhibitors
- Phosphodiesterase type 4 (PDE-4) Inhibitors
Atopic Dermatitis (Atopic Eczema) Treatment Market size was valued at x million in 2021 and is poised to grow at a CAGR of x% during 2023-29. Atopic dermatitis atopic eczema. is a type of inflammatory disease which is of unknown origin usually starts in early infancy, but also affects a major number of adults. Atopic dermatitis results in itchy, red, swollen and cracked skin. Many people with atopic dermatitis may develop hay fever and asthma. The causes are unknown but it is found to involve inherited, immune system dysfunction, environmental exposure and difficulties in permeability of skin. Multiple factors such as seasonal allergies, low humidity, exposure to harsh detergents & soaps, and cold weather can trigger or worsen atopic dermatitis, including. The atopic dermatitis treatment includes mainly steroid creams and moisturizers. Often, antibiotics are used when there is a skin infection. Diagnosis is done by physical examination and in some cases, biopsy is performed. Atopic Dermatitis Treatment aims to control inflammation and relieving itching. Atopic dermatitis treatment market is expected to grow at steady state during the forecast period. Market players are focusing on research and development to discover new drugs to treat atopic dermatitis. Several global and regional players competing for the market share. Companies adopting several strategies such as acquisitions, mergers and partnering with other players to withstand the competition and grow their market share. For instance, AstraZeneca has entered into an agreement with LEO Pharma A/S, for the global license to tralokinumab in skin diseases. Tralokinumab is a potential new medicine that is being developed in phase II clinical trials for the treatment of patients with atopic dermatitis. In December 2016, Novartis acquired UK based Ziarco Group and expanded its R&D portfolio with once daily oral H4 receptor agonist, ZPL389, that is being developed for the treatment of atopic dermatitis. In addition, new classes of products are launched targeting atopic dermatitis other than the traditional classes such as corticosteroids. This gives the health care professionals to choose various alternatives. For instance, in February 2017, Pfizer got FDA approval for Eucris, a non-steroidal topical phosphodiesterase-4 inhibitor that is used for treatment of mild to moderate atopic dermatitis.
Sanofi: Dupixent (Dupilumab) - Launched in 2017.
Regeneron Pharmaceuticals: Dupixent (Dupilumab) - Launched in 2017.
Pfizer: Eucrisa (Crisaborole) - Launched in 2016.
Eli Lilly: Olumiant (Baricitinib) - Initially approved for rheumatoid arthritis in 2018, and received FDA approval for atopic dermatitis in 2021.
Incyte Corporation: Olumiant (Baricitinib) - Initially approved for rheumatoid arthritis in 2018, and received FDA approval for atopic dermatitis in 2021
Fastest Growing Market
Global Atopic Eczema treatment market is driven by increased R&D funding to develop biologics and development of targeted therapies for atopic dermatitis. In addition increased incidence of atopic dermatitis, new product launches, and increased awareness about the symptoms of atopic dermatitis expected to further boost the market. However, availability of the generic drugs and high cost of dermatology drugs are expected to hamper the market during the forecast period.
atopic dermatitis (Atopic Eczema) treatment market is projected to expand at a CAGR of x% during the forecast period
Pfizer Inc, Anacor Pharmaceutical Inc, Regeneron Pharmaceuticals, Inc, Sanofi S.A, Novartis AG
North America is the fastest-growing region for the atopic dermatitis (Atopic Eczema) treatment market